Evidence map›Paper›PMID 37814012›Full record

ArticleNature cancer2023

Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.

Isao Miyazaki, Igor Odintsov, Keiji Ishida, Allan J W Lui, Masanori Kato, Tatsuya Suzuki, Tom Zhang, Kentaro Wakayama, Renate I Kurth, Ryan Cheng and 23 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

33 authors.

Isao Miyazaki *Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan. isao-miyazaki@taiho.co.jp.ORCID http://orcid.org/0009-0008-3742-1243
Igor Odintsov *Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Keiji IshidaTaiho Pharmaceutical Co. Ltd., Tsukuba, Japan.
Allan J W LuiDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-7624-3437
Masanori KatoTaiho Pharmaceutical Co. Ltd., Tsukuba, Japan.ORCID http://orcid.org/0009-0002-4918-8959
Tatsuya SuzukiTaiho Pharmaceutical Co. Ltd., Tsukuba, Japan.
Tom ZhangDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kentaro WakayamaTaiho Pharmaceutical Co. Ltd., Tsukuba, Japan.
Renate I KurthDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ryan ChengDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hidenori FujitaTaiho Pharmaceutical Co. Ltd., Tsukuba, Japan.
Lukas DelasosDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Morana VojnicDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Inna KhodosAntitumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Yukari YamadaTaiho Pharmaceutical Co. Ltd., Tsukuba, Japan.
Kota IshizawaHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Marissa S MattarDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kaoru FunabashiTaiho Pharmaceutical Co. Ltd., Tsukuba, Japan.
Qing ChangAntitumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Shuichi OhkuboTaiho Pharmaceutical Co. Ltd., Tsukuba, Japan.
Wakako YanoTaiho Pharmaceutical Co. Ltd., Tsukuba, Japan.
Ryuichiro TeradaTaiho Pharmaceutical Co. Ltd., Tsukuba, Japan.
Claudio GiulianoHelsinn Healthcare SA, Lugano, Switzerland.ORCID http://orcid.org/0000-0003-1600-544X
Yue Christine LuDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Annalisa BonifacioHelsinn Healthcare SA, Lugano, Switzerland.
Siddharth KunteDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Monika A DavareDepartment of Pediatrics, Oregon Health Sciences University, Portland, OR, USA.ORCID http://orcid.org/0000-0003-1802-7597
Emily H ChengHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-3595-2648
Elisa de StanchinaAntitumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Emanuela LovatiHelsinn Healthcare SA, Lugano, Switzerland.
Yoshikazu IwasawaTaiho Pharmaceutical Co. Ltd., Tsukuba, Japan.
Marc LadanyiDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Romel SomwarDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. somwarr@mskcc.org.ORCID http://orcid.org/0000-0002-5282-6889

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID37814012
PMCPMC10597837

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.